MNG127
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.400
- WNT_BETA_CATENIN_SIGNALING+0.350
- CHOLESTEROL_HOMEOSTASIS+0.312
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.288
- ESTROGEN_RESPONSE_EARLY+0.282
- MYC_TARGETS_V2+0.279
- ESTROGEN_RESPONSE_LATE+0.258
- UV_RESPONSE_UP+0.237
- MITOTIC_SPINDLE+0.230
- HEME_METABOLISM+0.209
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.401
- ANGIOGENESIS-0.299
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.291
- OXIDATIVE_PHOSPHORYLATION-0.280
- KRAS_SIGNALING_UP-0.265
- INTERFERON_GAMMA_RESPONSE-0.259
- INTERFERON_ALPHA_RESPONSE-0.179
- SPERMATOGENESIS-0.170
- APICAL_SURFACE-0.166
- PANCREAS_BETA_CELLS-0.158
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1111 | — | — | 0.788 |
| 2 | MNG702 | — | — | 0.752 |
| 3 | SRR8392893 | — | cohortSQ2 | 0.719 |
| 4 | MNG1104 | — | — | 0.703 |
| 5 | TCGA-CV-7430-01A-11R-2132-07 | — | — | 0.688 |
| 6 | DRR168527 | — | — | 0.678 |
| 7 | ca41a924-f82c-4e83-996b-35261387ad3a | — | — | 0.674 |
| 8 | MNG1079 | — | — | 0.657 |
| 9 | MNG683 | — | — | 0.657 |
| 10 | DRR168551 | — | — | 0.655 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.312 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.288 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.282 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.279 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.258 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.237 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.209 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.208 | Idelalisib | — uncovered |
| APOPTOSIS | 0.164 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.161 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.147 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.143 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.126 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.126 | Remibrutinib | — uncovered |